Role of methotrexate in the management of Crohn disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 44, Issue 4, 2007, Pages 427-430

  Ravikumara, Madhur ^a   Hinsberger, Ann ^a   Spray, Christine H ^a  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

Children; Crohn disease; Infliximab; Methotrexate

Indexed keywords

AZATHIOPRINE; FOLIC ACID; INFLIXIMAB; MESALAZINE; METHOTREXATE; STEROID;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; COLITIS; COLON CROHN DISEASE; CROHN DISEASE; CUSHINGOID SYNDROME; DATA BASE; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; ILEOSTOMY; IMMUNOMODULATION; INTESTINE FISTULA; MALE; MEDICAL RECORD; NEUTROPENIA; PATIENT COMPLIANCE; PEDIATRICS; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; SIDE EFFECT; SORE THROAT; TREATMENT DURATION; ULCER; ULCERATIVE PERIANAL DISEASE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ADOLESCENT; CHILD; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE;

EID: 34147156806     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3180320689     Document Type: Article

References (27)

1. Sawczecko A, Sandhu BK, Logan RFA, et al. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet 2001;357:1093-4.
2. Hanauer SB. Inflammatory bowel disease: drug therapy. N Engl J Med 1996;334:841-8.
3. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-2.
4. Hawthorne AB. Methotrexate: a useful alternative in Crohn's disease. Gut 2001;49:9-10.
5. Homan M, Baldassano RN, Mamula P. Managing complicated Crohn's disease in children and adolescents. Nat Clin Pract Gastroenterol Hepatol 2005;2:572-9.
6. Kozarek RA, Patterson DJ, Geland MD, et al. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-6.
7. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332:292-7.
8. Alfadhi AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2003;1:CD003459.
9. Mack DR, Young R, Kufman SS, et al. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998;132:830-5.
10. Stephens MC, Baldassano RN, York A, et al. The bioavailability of oral methotrexate in children with inflammatory disease. J Pediatr Gastronterol Nutr 2005;40:445-9.
11. Deslanders C. Methotrexate - an alternative treatment in pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 1999;29:520.
12. Rosh J, Youssef N, Schuckalo S, et al. Efficacy of methotrexate as a maintenance agent in pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 2003;37:392.
13. Uhlen S, Belbouab R, Narebski K, et al. Efficacy of methotrexate in the treatment of pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 2006;42:E44.
14. Shroder O, Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol 2003;98:530-7.
15. Cronstein BM, Naime D, Ostad E. The anti-inflammatory mechanism of methotrexate. J Clin Invest 1993;92:2675-82.
16. Seitz M. Molecular and cellular effects of methotrexate. Curr Opin Rheumatol 1999;11:226-32.
17. Balis FM, Miro J, Reaman GH, et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988;6:1882-6.
18. Kozarek RA, Patterson DJ, Geland MD, et al. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-6.
19. Kurnik D, Loebstein R, Fishbein E, et al. Bioavailability of oral vs subcutaneous low dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther 2003;18:57-63.
20. Aberra FN, Lichtenstein GR. Monitoring of inflammatory bowel disease. Aliment Pharmacol Ther 2005;21:307-19.
21. Ardizzone S, Bollani S, Manzionna G, et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator blind study. Dig Liver Dis 2003;35:619-27.
22. Feagan BG, Alfadhi A. Methotrexate in inflammatory bowel disease. Gastroenterol Clin North Am 2004;33:407-20.
23. Roenigk HH Jr, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988;19:145-56.
24. Kremer JM, Alarcon JS, Lightfood RW Jr, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994;37:316-28.
25. Kozarek RA, Bredfeldt JE, Rosoff JE, et al. Does chronic methotrexate cause liver toxicity when use for refractory inflammatory bowel disease? Gastroenterology 1991;100:A223.
26. Te HS, Schiano TD, Hanauer HJ, et al. Hepatic effects of long term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroentrol 2000;95:3150-6.
27. Fraser AG, Morton D, McGovern D, et al. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16 (4):693-7.